Insmed Inc (INSM)vsNuvalent Inc (NUVL)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NUVL
Nuvalent Inc
$98.00
+1.92%
HEALTHCARE · Cap: $7.56B
Smart Verdict
WallStSmart Research — data-driven comparison
NUVL leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NUVL
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NUVL
The primary concerns for NUVL are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NUVL is a value play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.32 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NUVL generates stronger free cash flow (-73M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 25/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, the company aims to create innovative treatments that specifically target genetic mutations responsible for tumor growth, thereby improving patient outcomes and minimizing side effects. With a robust pipeline of highly selective therapies, Nuvalent is strategically positioned within the precision oncology market, making it well-equipped to seize emerging opportunities in the rapidly evolving biotechnology sector. The company’s relentless commitment to advancing cancer treatment underscores its potential to significantly impact patient care in oncology.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?